Retrograde popliteal access to treat femoropopliteal artery occlusive disease
- PMID: 29503002
- DOI: 10.1016/j.jvs.2017.12.022
Retrograde popliteal access to treat femoropopliteal artery occlusive disease
Abstract
Objective: Retrograde popliteal artery (RPA) access to treat superficial femoral artery and popliteal artery disease is an option when treatment through common femoral artery (CFA) access is not possible. Our goal was to compare the safety and efficacy of RPA access with CFA access for treatment of femoral and popliteal artery lesions.
Methods: The Vascular Quality Initiative was queried for all patients undergoing RPA access from 2010 to 2016 for symptomatic peripheral arterial disease. These were compared with standard CFA access. Patients with acute limb ischemia were excluded. Preoperative, operative, and postoperative data were analyzed. Perioperative and 6-month outcomes were analyzed. Multivariable analysis was used to assess the effect of RPA access on amputation or death, major adverse limb event (MALE) or death, patency, and death.
Results: There were 30,074 patients with isolated superficial femoral and popliteal artery disease treated, 148 of whom had RPA access. Indications overall included claudication (56.3%), rest pain (13.9%), and tissue loss (29.8%). RPA access had a significantly lower rate of technical success compared with CFA access (80.4% vs 93.8%; P < .001). RPA access and CFA access were similar for rates of arterial dissection (8.3% vs 6.3%; P = .333), distal embolization (0% vs 1.2%; P = .183), access site hematoma (3.4% vs 3.1%; P = .849), and 30-day mortality (1.4% vs 1.1%; P = .789). There were no differences between RPA access and CFA access for unadjusted 6-month amputation-free survival (94.8% vs 96%; P = .747) or survival (934.3% vs 95.6%; P = .845). MALE-free survival (74.5% vs 83.5%; P = .016) and patency (70.3% vs 83.1%; P < .001) were significantly lower in the RPA access group. Multivariable analysis showed no differences between patients who were successfully treated by RPA access and CFA access for amputation-free survival (hazard ratio [HR], 1.24; 95% confidence interval [CI], 0.46-3.32; P = .669), MALE-free survival (HR, 1.57; 95% CI, 0.99-2.5; P = .057), and survival (HR, 0.86; 95% CI, 0.43-1.73; P = .675). RPA access was independently associated with loss of primary patency (HR, 1.91; 95% CI, 1.24-2.94; P = .003).
Conclusions: RPA access had lower technical success and primary patency compared with antegrade access at 6 months. There were no differences demonstrated between the two access techniques in perioperative morbidity and mortality or 6-month amputation, MALE, and survival. This technique should be considered when CFA access cannot be accomplished.
Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Endovascular Management of Severe Peripheral Artery Disease Isolated to the Popliteal Artery Shows Comparable Outcomes Regardless of Treatment Modality.Ann Vasc Surg. 2025 May;114:203-211. doi: 10.1016/j.avsg.2025.01.046. Epub 2025 Mar 5. Ann Vasc Surg. 2025. PMID: 40054603
-
Endovascular treatment of the common femoral artery in the Vascular Quality Initiative.J Vasc Surg. 2017 Apr;65(4):1039-1046. doi: 10.1016/j.jvs.2016.10.078. Epub 2016 Dec 29. J Vasc Surg. 2017. PMID: 28041804
-
Outcomes of bypass and endovascular interventions for advanced femoropopliteal disease in patients with premature peripheral artery disease.J Vasc Surg. 2021 Dec;74(6):1968-1977.e3. doi: 10.1016/j.jvs.2021.05.034. Epub 2021 Jun 6. J Vasc Surg. 2021. PMID: 34090986
-
Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis.J Endovasc Ther. 2020 Aug;27(4):647-657. doi: 10.1177/1526602820931559. Epub 2020 Jun 7. J Endovasc Ther. 2020. PMID: 32508220
-
Atherectomy plus drug-coated balloon versus drug-coated balloon only for treatment of femoropopliteal artery lesions: A systematic review and meta-analysis.Vascular. 2021 Dec;29(6):883-896. doi: 10.1177/1708538120985732. Epub 2021 Jan 21. Vascular. 2021. PMID: 33478353
Cited by
-
Augmented reality navigation to assist retrograde peroneal access for the endovascular treatment of critical limb ischemia.J Vasc Surg Cases Innov Tech. 2019 Nov 18;5(4):518-520. doi: 10.1016/j.jvscit.2019.06.004. eCollection 2019 Dec. J Vasc Surg Cases Innov Tech. 2019. PMID: 31768482 Free PMC article.
-
Alternative access for peripheral vascular interventions.J Vasc Surg Cases Innov Tech. 2023 May 24;9(3):101232. doi: 10.1016/j.jvscit.2023.101232. eCollection 2023 Sep. J Vasc Surg Cases Innov Tech. 2023. PMID: 37408940 Free PMC article.
-
State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet?J Soc Cardiovasc Angiogr Interv. 2022 Sep-Oct;1(5):100439. doi: 10.1016/j.jscai.2022.100439. Epub 2022 Aug 20. J Soc Cardiovasc Angiogr Interv. 2022. PMID: 36268042 Free PMC article.
-
Popliteal access for endovascular procedures in femoropopliteal artery occlusive disease.Postepy Kardiol Interwencyjnej. 2023 Sep;19(3):277-283. doi: 10.5114/aic.2023.131482. Epub 2023 Sep 27. Postepy Kardiol Interwencyjnej. 2023. PMID: 37854961 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical